ijms-logo

Journal Browser

Journal Browser

Epigenetic Dysregulation in Cancers: From Mechanism to Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 978

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
Interests: oncology; drug resistance; tumor microenvironment; epigenetics

Special Issue Information

Dear Colleagues,

Besides genetic alterations, from point mutations to chromosomal aberrations, epigenetics dysregulation is also involved in several features of carcinogenesis. Among these, the histone modifications and non-coding RNAs are the most well-characterized epigenetic hallmarks, playing a pivotal role in cancer initiation and progression. In this context, microRNAs have been recently investigated to evaluate their application as therapeutic agents in cancer treatment. Moreover, DNA methylation has attracted growing interest for its key role in the regulation of several cancer-related genes. In particular, promoter hypomethylation is strictly associated with the transcriptional activation of oncogenes, while the hypermethylation status of promoter regions induces tumor suppressor gene silencing. Despite recent evidence indicating that intragenic DNA methylation is actively involved in transcriptional regulatory processes and splicing, its functional role has not been completely elucidated yet. In this field, methylation hotspots have recently emerged as potential biomarkers for cancer diagnosis and prognosis. In this context, the recent advances in site-specific methylation/demethylation could represent a promising strategy to improve the outcomes of cancer treatment.

This Special Issue aims to provide an overview of the recent advances into the epigenetic phenomena affecting cancer-related gene expression, as well as the reliability of epigenetic hotspots in early cancer diagnosis. Furthermore, the latest clinical relevance of the main epigenetic markers is provided, representing a starting point for the development of new cancer treatment options. This Special Issue will contain original research articles, including in silico studies and full reviews.

Dr. Saverio Candido
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epigenetics
  • non-coding RNAs
  • microRNAs
  • histone modifications
  • chromatin remodeling
  • DNA methylation
  • 5-methyl-cytosine
  • biomarkers
  • cancer
  • promoter and body methylation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 1532 KiB  
Review
Impact of Histone Lysine Methyltransferase SUV4-20H2 on Cancer Onset and Progression with Therapeutic Potential
by Stela Papadaki and Christina Piperi
Int. J. Mol. Sci. 2024, 25(5), 2498; https://doi.org/10.3390/ijms25052498 - 21 Feb 2024
Viewed by 764
Abstract
Histone lysine methyltransferase SUV4-20H2, a member of the suppressor of variegation 4–20 homolog (SUV4-20) family, has a critical impact on the regulation of chromatin structure and gene expression. This methyltransferase establishes the trimethylation of histone H4 lysine 20 (H4K20me3), a repressive histone mark [...] Read more.
Histone lysine methyltransferase SUV4-20H2, a member of the suppressor of variegation 4–20 homolog (SUV4-20) family, has a critical impact on the regulation of chromatin structure and gene expression. This methyltransferase establishes the trimethylation of histone H4 lysine 20 (H4K20me3), a repressive histone mark that affects several cellular processes. Deregulated SUV4-20H2 activity has been associated with altered chromatin dynamics, leading to the misregulation of key genes involved in cell cycle control, apoptosis and DNA repair. Emerging research evidence indicates that SUV4-20H2 acts as a potential epigenetic modifier, contributing to the development and progression of several malignancies, including breast, colon and lung cancer, as well as renal, hepatocellular and pancreatic cancer. Understanding the molecular mechanisms that underlie SUV4-20H2-mediated effects on chromatin structure and gene expression may provide valuable insights into novel therapeutic strategies for targeting epigenetic alterations in cancer. Herein, we discuss structural and functional aspects of SUV4-20H2 in cancer onset, progression and prognosis, along with current targeting options. Full article
(This article belongs to the Special Issue Epigenetic Dysregulation in Cancers: From Mechanism to Therapy)
Show Figures

Figure 1

Back to TopTop